Daily Briefing – June 8: Oil shock, AI valuation pressure, Apple WWDC, Oracle earnings week, Marvell/Flex index flow and a major Roche–Nurix biotech deal

The June 8 briefing starts with risk appetite under pressure. Global stocks are trading defensively as fresh Middle East hostilities push oil higher, while investors continue to reduce exposure to the most crowded AI-linked names after last week’s semiconductor shock. The key message for Monday is simple: the market is not rejecting AI as a long-term theme, but it is becoming much less forgiving on valuation, margins, funding needs and guidance quality. Apple’s WWDC opens today and gives the market a direct test of consumer AI expectations, while Oracle’s fiscal Q4 results are scheduled for Wednesday after the close and will test the infrastructure side of the AI trade. Marvell and Flex also remain important because S&P Dow Jones Indices has selected both companies for S&P 500 inclusion, effective before the open on June 22. In biotech, the headline of the morning is Roche’s global collaboration with Nurix Therapeutics on bexobrutideg, a BTK degrader deal with a large upfront payment and milestone potential that puts targeted protein degradation back in the spotlight. FDA policy also stays relevant after the agency issued a June 2026 draft guidance on leveraging prior knowledge in human gene therapy products incorporating genome editing. For traders, today is a tape-control session: oil, yields, QQQ/SOXX stabilization, Apple’s AI reaction, MRVL/FLEX index demand and biotech deal flow are the cleanest places to watch.

• AAPL— Apple’s WWDC26 starts today, June 8, with the keynote and Platforms State of the Union; the event is the biggest consumer-AI sentiment test of the week.WWDC / AI
• ORCL— Oracle reports fiscal Q4 2026 results on Wednesday, June 10, after the close, with its conference call/webcast scheduled for 4:00 p.m. Central Time.AI Earnings
• MRVL— Marvell remains one of the cleanest Monday watch names because it combines AI custom-silicon exposure with upcoming S&P 500 inclusion before the open on June 22.AI / Index
• FLEX— Flex joins Marvell in the S&P 500 rebalance, adding a benchmark-flow angle to contract manufacturing, data-center hardware and AI supply-chain exposure.Index Flow
• AVGO— Broadcom stays the AI valuation-reset name after the semiconductor selloff showed that high-quality AI exposure still needs to clear a much higher expectations bar.AI Reset
• NVDA— Nvidia remains the leadership anchor, but the group’s Monday reaction matters because AI leaders are now trading against oil risk, rate pressure and valuation fatigue.AI Anchor
• AMD / INTC— AMD and Intel remain chip-breadth checks; today’s key signal is whether secondary semiconductor names stabilize or continue to lag the leaders.Chip Breadth
• NRIX— Nurix Therapeutics announced a global Roche collaboration for bexobrutideg/NX-5948, putting BTK degradation, oncology/immunology optionality and non-dilutive capital back on trader screens.Biotech Deal
• RHHBY / RO— Roche adds Nurix’s BTK degrader to a broader plan across B-cell malignancies, immunology and neurology, reinforcing large-pharma appetite for targeted protein degradation.Pharma M&A
• SNY— Sanofi’s press-release feed shows June 8 EU approval of subcutaneous Sarclisa as the first anticancer treatment administered via an on-body injector.EU Approval
• PHAR— Pharming remains on the FDA calendar after acceptance of the Joenja/leniolisib pediatric APDS sNDA resubmission, with an October 24, 2026 PDUFA target date.FDA / Rare Disease
• URGN / TEVA— UroGen and Teva remain legal/IP watch names after the JELMYTO settlement, with potential Teva generic entry beginning September 15, 2030 if approved by FDA.Legal / IP
• CELC— Celcuity stays on financing watch after pricing upsized convertible senior notes last week, with the offering expected to close today, June 8.Financing
• SMMT— Summit remains an oncology watch as management presents at the Goldman Sachs healthcare conference today while investors keep the ivonescimab PDUFA setup in focus.Healthcare Conf.
• COGT / BBIO / VERA / CORT / CELC / CAPR— The FDA catalyst basket stays important because a defensive tape usually rewards clean regulatory timing, strong cash runway and fewer financing surprises.PDUFA Watch

• Oil is the first macro signal— Fresh Middle East hostilities are pushing crude higher and keeping inflation expectations, energy equities and transport margins in focus.Oil / Geo
• Global stocks are defensive— The market is dealing with a double pressure point: geopolitical risk through oil and valuation risk through crowded AI trades.Risk-Off
• AI is under stricter review— The long-term infrastructure theme remains intact, but investors now want upside, margins, backlog visibility and funding discipline at the same time.AI Valuation
• Semiconductors need repair— SOXX and the large AI-chip names must stabilize quickly or the selloff can spread from valuation reset into broader growth derisking.Semis
• Yields remain a problem— After last week’s jobs-driven rate repricing, Treasury yields remain one of the main constraints on growth, small caps and cash-burning biotech.Rates
• Apple is the product test— WWDC will show whether the market still pays for AI software stories or now demands clearer proof of adoption, monetization and device-cycle impact.AAPL
• Oracle is the infrastructure test— Oracle’s June 10 report matters because traders want proof that cloud backlog and AI demand can support margins and capex.ORCL
• Inflation data comes next— CPI and PPI later this week will decide whether the rate-pressure story cools or becomes another headwind for risk assets.CPI / PPI
• FDA policy watch— FDA’s June draft guidance on leveraging prior knowledge in gene therapy development is constructive for platform sponsors, but it is draft and non-binding.Regulatory
• Biotech selectivity rises— After ASCO and with rates still in focus, the tape is separating real registrational paths from early signals, biomarker stories and capital-hungry programs.Biotech
• Deal flow matters— The Roche–Nurix deal is important because large upfront biotech transactions can support sentiment even when the broader market is defensive.Deals